Skip to content

Category Archives: Pouch enlargement or dilatation of the gastrojejunostom

GI Dynamics > Clinical-stage medical device company > New noninvasive approaches to treat obesity > Type 2 diabetes > Related metabolic diseases > EndoBarrier technology > EndoBarrier Gastrointestinal Liner > Orally delivered > Removable device > Lines portion of small intestine > Immediate metabolic control with less risk

Has GI Dynamics developed therapies resulting in weight loss and improved glycemic control? Is the technology designed to deliver immediate metabolic control by modifying metabolic pathways? Will EndoBarrier application data be presented at the 1st World Congress on Interventional Therapies for Type 2 Diabetes?

IIP > read on here > http://www.earthtimes.org…
Data from Clinical Trial of EndoBarrier(TM) […]

Transoral endoscopic anchor placement system > Gastric bypass pouch and stoma reduction > Successful feasibility study > Technology assessment > Daniel Herron > Desmond Birkett > Chris Thompson > Marc Bessler > Lee Swanström

How successful is the technology for the clinical circumstances for which it is being evaluated? Will there be a technology assessment by the American Society for Gastrointestinal Endoscopy ASGE following the feasibility of reducing the stoma diameter using transoral endoscopic suturing techniques? Will there be an adequate randomized clinical trial in the near future to […]

As America Gets Bigger > Serious social and psychological dimensions > National Eating Disorder > Centers for Disease Control and Prevention CDC > Call to Action to Prevent and Decrease Overweight and Obesity > National Health and Nutrition Examination Survey NHANES > Diabetes mellitus > Cardiovascular disease > Hypertension and stroke > Certain forms of cancer > Increased risk of premature death > Serious chronic conditions > Reduced overall quality of life

Is surgical treatment for obesity a good and effective treatment for preventing the life-threatening complications and serious degenerative problems associated with pathological obesity? Do drug and medical device companies cash in to unprecedented degrees? Will overweight- and obesity-attributable spending continue to increase and government will continue to finance a sizable portion?

IIP > read on here […]